Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis, Systemic 1Mastocytosis 1Mast Cell Activation Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

midostaurin 1masitinib 1Phlebotomy 1Dasatinib 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Mastocytosis, Systemic × Cladribine × Clear all
NCT01602939 2016-08-29

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 2/3 Unknown
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡